Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ViiV Healthcare
Three Firms Sign Up With MPP For Long-Acting Cabotegravir
Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.
Medicaid Coverage For PrEP Without Restrictions, Cost Sharing Backed By President’s Budget
Legislation could facilitate faster access without cost sharing or restrictions for new HIV pre-exposure prophylaxis. The White House said its budget proposal to expand Medicare price negotiation would save $160bn more than the Inflation Reduction Act's existing negotiation provisions.
ViiV’s Bid To Switch HIV Patients To Cabenuva Boosted By Biktarvy Head-To-Head
A new head-to-head proves Cabenuva is a match for Gilead’s Biktarvy, which should boost uptake of the long-acting HIV treatment.
Japan Q3 Roundup: Forex Impacts Majors Amid New Product Growth Expectations
Amid ongoing impact from exchange rates, Japan's five largest pharma firms showed mostly positive growth in the fiscal nine-month period. Enhertu will continue to drive Daiichi Sankyo, while Shionogi is forecasting record-breaking revenue on oral COVID-19 drug Xocova and Eisai is rolling out closely-watched Alzheimer's contender Leqembi.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.